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A B S T R A C T
Despite anticonvulsant efﬁcacy in animal models of generalized epilepsy, levetiracetam was not
effective in the maximal subcutaneous PTZ model in mice and rats.
Aim of this study was to assess the efﬁcacy of levetiracetam (LEV) against submaximal, s.c. MET test
(PTZ at the dose of 70 mg/kg) acute seizures in Wistar rats, in comparison to valproic acid (VPA).
Thirty male Wistar rats (P42) were divided in three drug-treatment groups (10 rats in each group) as
follows: valproic acid, levetiracetam, and controls. All animals were tested for seizure threshold at age
P50. VPA (110 mg/kg) and LEV (108 mg/kg)were freshly dissolved in saline and injected i.p. in 2–3 ml/kg,
15 and 30 min, respectively, before pentylenetetrazol (PTZ) injection at the dose of 70 mg/kg.
The average latency of the seizure type 3 (generalized clonic seizure with loss of righting reﬂexes)
signiﬁcantly differed between controls and the drug-treated animal groups (p  0.02). The average
duration of the seizure type 2 (threshold seizure) was signiﬁcantly longer in both groups compared to
controls (<0.02).
In conclusion, LEV plays a role against seizures triggered by subcutaneous PTZ injection given at
submaximal doses in rats, as demonstrated by a signiﬁcant increase in duration of the seizure type 2
(threshold seizure).
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Levetiracetam (LEV) is a new generation drug which was
effective for the treatment of focal seizures with or without
secondary generalization, as well as tonic-clonic and myoclonic
generalized seizures.1–4 Recent report conﬁrmed LEV to be also
effective in controlling absence seizures,5 and placebo-controlled
trials with this drug are ongoing.
In preclinical studies, levetiracetam has been shown active in
animal models that are believed to represent generalized seizures.
The expression of seizure activity was prevented in both
audiogenic susceptible mice6 and rats.7 A marked suppression of
the mean duration of spike-and-wave discharges was also
obtained by levetiracetam in rats from the Genetic Absence
Epilepsy Rats from Strasbourg (GAERS) strain even at the lowest* Corresponding author at: Clinic of Child and Adolescent Neuropsychiatry,
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doi:10.1016/j.seizure.2010.03.004tested dose. A similar suppression of pentylenetetrazol (PTZ)-
induced spike-and-wave discharges was also observed with an i.p.
dose of 17 mg/kg6.
Despite such a clinical evidence in humans and animal models
of generalized epilepsy, LEV was not effective at doses up to
500 mg/kg in the experimental animalmodel ofmaximal s.c. PTZ at
the dose of 90 mg/kg, in mice and rats.8 This model has been
hypothesized to correlate with the efﬁcacy of an anticonvulsant
drug against myoclonic and clonic seizures in humans.9 Yet, the
type and severity of the generalized seizures induced in this model
are related to the dose and route of PTZ injection.10,11
It is well accepted that maximal pentylentetrazole test (MMT)
and maximal electroshock test (MES) are considered ‘‘suprathres-
hold’’ tests, while ‘‘threshold tests’’ include the PTZ infusion test
and the threshold electroconvulsive test (ECS). Among these, the
subcutaneous pentylentetrazol (scMET) test12 may be included,
since a lower dose of PTZ (70 mg/kg) is given instead of 90 mg/kg,
as in the MMT test.
While suprathreshold tests are best suited to study maximal
seizures in rodents, consisting of tonic forelimb and hindlimb
extension, and are used in drug development tomodel tonic-clonicvier Ltd. All rights reserved.
Fig. 1. Latency (seconds) of different seizure types in the three groups of rats.
*p  0.02 (Dunnett t-test, two-sided (seizure latency in controls vs. the other
groups).
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(threshold) seizures consisting of face and forelimb clonic jerks,
and are used in drug development to model myoclonic seizures in
humans.9
Such an experimental model may indeed contribute to better
disclose the anticonvulsant properties of a new drug, i.e. by
comparing them with those of a well established one.
In order to further assess the actual efﬁcacy of LEV in such a
seizure model, speciﬁc for generalized seizures of clonic and
myoclonic type, we evaluated LEV efﬁcacy against s.c. MET test
(PTZ at the dose of 70 mg/kg) acute seizures in Wistar rats.
2. Materials and methods
2.1. Animals and diet
Thirty male Wistar rats (Harlan Italy, Milan, Italy) were housed
in groups of two in polycarbonate cages at a temperature of 25 8C,
on an alternating 12-h light/12-h dark cycle with lights on at
06:00 h.
Animals arrived at 42 days of age (P42) and were fed rodent
chow (F1515 Rodent diet, AIN-76A, 1/2 pellets by Bio-Serv,
Frenchtown, NJ, USA) and provided water ad libitum for 8 days
before initiation of the experiment.
All animals were maintained within conditions speciﬁed in
approved Institutional Animal Care and use Committee protocols.
The experiment protocol was previously approved by the local
Ethic Committee.
2.2. Seizure threshold
After maintenance on a free chow diet, all animals were divided
in three drug-treatment groups (10 rats in each group) as follows:
valproic acid, levetiracetam, and controls.
Valproic acid (VPA), supplied by Sanoﬁ-Aventis as puriﬁed
product, was dissolved in 0.9% NaCl, sterile ﬁltered (0.2 mm,
Coster), and injected intraperitoneally (i.p.) at the dose of 110 mg/
kg. This VPA dosage was reported to be the ED50 in Wistar rats by
Lo¨scher et al.9.
Levetiracetam (LEV), supplied by UCB-Belgium as puriﬁed
product, was dissolved in 0.9% NaCl sterile ﬁltered (0.2mmol,
Coster) and injected intraperitoneally (i.p.) at the dose of 108 mg/
kg. This dose, effective in the e.v. PTZ model 13), was chosen to be
assessed in a submaximal s.c. PTZ seizure model.
Controls were given an equivalent volume of saline (i.p.). All
animals were tested for seizure threshold at age P50.
Pentylenetetrazol (PTZ) (Sigma Chemical Co.) was dissolved in
bacteriostatic saline (Abbott) to a concentration of 10 mg/ml and
injected at the dose of 70 mg/kg subcutaneously into a loose fold of
skin on the back of the neck of the animals. The PTZ seizure
threshold test was administered according to a modiﬁcation of the
procedure by Krall et al.14 The dose of 70 mg/kg was considered
intermediate between themaximal dose (90 mg/kg) and 50 mg/kg,
which was determined in a separate experiment as the minimal
dose required to induce generalized seizures in 100% of our rats
within approximately 30 minutes after PTZ injection.
Valproic acid (110 mg/kg) and levetiracetam (108 mg/kg) were
freshly dissolved in saline and injected i.p. in 2–3 ml/kg, 15 and
30 min (time to maximum serum concentration) before PTZ
injection, respectively.9,15,16
Soon after PTZ administration, each rat was video-taped and
monitored for 1 h, and the different seizure types (in order of
appearance) were rated as follows: 0, no seizures; 1, generalized
myoclonic twitches; 2, generalized clonic seizure without loss of
righting reﬂexes (‘‘threshold seizure’’); 3, generalized clonic
seizure with loss of righting reﬂexes; 4, loss of righting reﬂexeswith forelimb tonus; 5, loss of righting reﬂexes with hindlimb
tonus.9
Since PTZwas given at the dose of 70 mg/kg, that is less than the
CD97 (90 mg/kg by Lo¨scher et al.9), rats with no seizures (seizure
type 0) were excluded from the study. Following the same reason,
the videomonitoring of each ratwas prolonged for at least 1 h after
PTZ injection.
All animals were seizure naı¨ve when tested and each was
subjected to seizure testing only once. Seizures were always
induced between 13:00 and 17:00 to minimize possible compli-
cating effects of circadian rhythms17.
2.3. Statistical analysis
One-way analysis of variance was performed to evaluate the
relationship between groups of treatment and Dunnett t-test was
used to compare all other groups against control. A p value below
0.05 was considered signiﬁcant.
3. Results
All rats developed seizures leading to exitus. While there was
no signiﬁcant difference among the three groups as regards
the start of the seizures type 1 and 2, the average latency of the
seizure type 3 signiﬁcantly differed between controls and the
other two groups (p  0.02; Dunnett t-test, two-sided). Further-
more, the average latency (in seconds) was essentially over-
lapping both in VPA and LEV group (1159.43  928.0 and 1477.43
 615.0) (Fig. 1).
Fig. 2 shows the mean duration  SD of the seizures type 1 and 2
(seizure threshold) in each group of animals. While duration of the
seizure type 1 was only slightly increased in the VPA group, the
seizure type 2 lasted signiﬁcantly longer in both groups, compared to
controls (p  0.02).
4. Discussion
In the present study, levetiracetam has increased, to the same
extent of valproic acid, the seizure threshold in rats that were
injected with s.c. PTZ at the dose of 70 mg/kg. In previous studies,
levetiracetam resulted ineffective in the experimentalmodel of s.c.
Fig. 2. Mean duration of seizure 1 and 2 after s.c. PTZ 70 mg/kg in Wistar rats.
*p  0.02 (Dunnett t-test, two-sided; seizure type 2 in controls vs. the other groups).
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generalized clonic seizure with loss of righting reﬂexes in 97% of
the rats (CD97).9
A lower dose of PTZ (70 mg/kg) probably allowed the
anticonvulsant action of levetiracetam to emerge also in this
experimental model of acute induced generalized seizures.
Similarly, a lower dose of s.c. PTZ (50 mg/kg) disclosed seizure
protection against seizures in Wistar rats fed the ketogenic diet.19
This data explainswhy anticonvulsant drugs, as vigabatrin and
progabide, were also ineffective in the s.c. PTZ model (supra-
threshold test), while they were effective in the i.v. PTZ seizure
model.
The generalized clonic seizure type 2, speciﬁcally correlated
with the seizure threshold by Swinyard11 in this experimental
model, lasted signiﬁcantly longer in both the drug-treated animal
groups than controls. Transition to the seizure type 3 (initial loss of
the righting reﬂexes with generalized clonic seizures) was thus
delayed in the same groups of rats.
The latency of the seizure type 2was, conversely, not inﬂuenced
by any of the tested drugs. This result is in keeping with the fact
that seizure type 2 (generalized clonic) is the most suitable to
assess the anticonvulsant potency in the s.c. PTZ model, while
seizure type 1 (myoclonic twitches) is best indicated for studying
seizure threshold in the i.v. PTZ model.9,11
The potency of an anticonvulsant drug against PTZ-induced
seizures type 2 seems, further, to predict anticonvulsant activity
against myoclonic and/or clonic seizures in humans more than
absence seizures. Lo¨scher et al.,9 in fact, suggest that drugs like
phenobarbital and primidone, neither of which exerting ther-
apeutic effects against absence seizures in humans, are effective in
the PTZ seizure model, similarly to valproate and ethosuximide.
Data coming from this experiment, based indeed on submax-
imal s.c. PTZ doses, show an anticonvulsant action of levetiracetam
closely paralleling that of valproic acid. They are therefore in
keeping with the clinical efﬁcacy of valproic acid20 and levetir-
acetam against such a kind of epileptic seizures in humans.5
Nonetheless, submaximal doses of PTZ may be hypothesized to
involve pharmacodinamic interactions other than those implicated
in the supramaximal s.c. PTZ model, for which the intrinsic
mechanisms are not well deﬁned.
Sequencing of the different seizure types is however over-
lapping in both seizure models, somewhat meaning the involve-
ment of the same brain networks.
Video monitoring lasting at least 1 h was necessary because of
the potential increase in latency of the different seizure types dueto the lower PTZ dose. Potential inter-animal variability of PTZ
absorption from the subcutaneous compartment was minimized
by a sufﬁcient number of rats in each group with a homogeneous
strain, body weight and age.
Seizures could, therefore, develop within or far beyond 30 min
after PTZ was injected subcutaneously.
Both drugs were tested at the time of maximum effect as
determined in MES experiments,9,18 because it is unlikely that the
time of peak effect is different in different seizure models.9
In conclusion, this trial shows levetiracetam to play a role
against seizures triggered by subcutaneous PTZ injection given at
submaximal doses in rats, as demonstrated by a signiﬁcant
increase in duration of the ‘‘threshold’’ seizure type 2 and latency
of the seizure type 3. These data are in keeping with the clinical
efﬁcacy of LEV against generalized tonic-clonic and myoclonic
seizures in humans.
Further, this study conﬁrmed the advantages of the submax-
imal s.c. PTZ test, compared to the PTZ tail vein infusion model,
consisting of its simplicity and possibility of fast and simultaneous
assessment of several seizure parameters.19While the PTZ infusion
model can accurately evaluate the threshold of seizure onset, the
s.c. MET model allows to assess the spreading of the different
seizure types according to their origin and diffusion in the different
brain networks such as forebrain (clonic seizures) or brain stem
(tonic seizures).
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